The ipamorelin research, study by study: skeletal first, mechanism second, humans third.

Before the details

Ipamorelin research is mostly animal research with a thin human edge. The strongest, most reproducible signal is skeletal: in rats, ipamorelin makes long bones grow faster and accumulate more mineral, in a way that tracks the dose. The mechanism is well mapped — it flips on the ghrelin receptor in the pituitary gland and fires a clean burst of growth hormone, without the cortisol spike older peptides cause. The human side is small: one pharmacology study that measured how fast the drug clears, and one trial for post-surgery bowel recovery that did not work. This page walks each study in plain terms, keeps the numbers attached to the paper that produced them, and flags every place the evidence is preclinical rather than proven in people. The ghrelin receptor referenced throughout is GHS-R1a, the same receptor the hunger hormone ghrelin uses.

Longitudinal bone growth: the dose-response that defines the skeletal lens

The anchor finding is a clean dose-response in adult female rats. Subcutaneous ipamorelin at 18, 90 and 450 microg/day — divided three times daily for 15 days — raised the longitudinal bone growth rate from 42 microm/day on vehicle to 44, 50 and 52 microm/day, stepwise with dose ^[2]. The detail that makes it interesting: total IGF-1, the IGF-binding proteins, and bone-turnover markers did not measurably change. A skeletal effect that scales with dose while the systemic growth-factor reading stays flat argues for a partly local, growth-hormone-pulse-driven mechanism rather than a simple rise in circulating IGF-1 ^[2].

The characterization was deliberately short — 15 days — so it speaks to growth rate, not to lifelong skeletal outcomes. It remains the single most-cited piece of ipamorelin's bone literature and the reason this site reads the molecule through a bone-skeletal lens.

Bone mineral content and the steroid-rescue data

Two further rat studies extend the skeletal picture in different directions. Continuous ipamorelin 0.5 mg/kg/day by subcutaneous osmotic minipump for 12 weeks raised total tibial and vertebral bone mineral content on DXA in young female rats versus vehicle, while cortical volumetric bone mineral density was unchanged ^[3]. The reading is dimensional: bones got larger and carried more total mineral, but the density of the cortex itself held — growth by expansion, not by densification.

Against a glucocorticoid headwind, ipamorelin 100 microg/kg three times daily for 3 months (alongside methylprednisolone 9 mg/kg/day) raised the periosteal bone formation rate roughly four-fold versus the steroid alone in 8-month-old female rats, and increased maximum tetanic muscle tension ^[4]. A companion study showed the growth-hormone response to ipamorelin was not blunted by methylprednisolone, and that combining the two raised IGF-1 and improved body-weight recovery versus steroid alone ^[5] — ipamorelin's pulse survives a glucocorticoid load.

Mechanism: GHS-R1a selectivity, in one figure

Ipamorelin's mechanism is its selling point. In the 1998 founding paper it released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious swine — swine ED50 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6 — but did not raise ACTH or cortisol above the GHRH-induced level even at doses more than 200-fold above its growth-hormone ED50 ^[1]. That clean separation between growth-hormone release and stress-hormone release is what "first selective growth hormone secretagogue" means.

The route is GHS-R1a agonism on pituitary somatotrophs: receptor activation drives a Gq/phospholipase-C calcium signal that releases growth hormone ^[1]. Because this is mechanistically distinct from the GHRH receptor's cAMP pathway, the two are complementary — the pharmacological basis for combining ipamorelin with a GHRH analog. Ipamorelin's sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, derives from GHRP-1 by removing the central Ala-Trp dipeptide, and the non-natural Aib and D-amino-acid residues give it protease resistance.

Ipamorelin cjc-1295

The ipamorelin cjc-1295 pairing is the most-searched ipamorelin topic, and its rationale is mechanistic, not trial-proven. CJC-1295 is a GHRH analog that acts on the GHRH receptor (a cAMP pathway); ipamorelin is a ghrelin-receptor agonist acting on GHS-R1a (a calcium pathway). Because the two routes are distinct and complementary ^[1], co-administration is expected to amplify the growth-hormone pulse beyond either agent alone. A 2026 orthopaedic narrative review reported that CJC-1295 combined with ipamorelin improved maximum tetanic muscle tension in a glucocorticoid-induced muscle-loss model in mice — while stressing the evidence is limited to animal studies ^[16]. The combination itself has not been tested in a controlled human outcome trial; its support is the separate single-agent pharmacology of each peptide ^{[16] [1]}.

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison across two different drug classes, not two versions of one thing. Sermorelin is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor; a clinical review frames it as a way to restore growth-hormone secretion in adult-onset growth-hormone insufficiency ^[15]. Ipamorelin is a GHRP (growth-hormone-releasing peptide) that acts on the separate ghrelin receptor ^[1]. The practical contrast: sermorelin works upstream through the GHRH route, while ipamorelin works through the ghrelin route and adds GHS-R1a selectivity (no cortisol or prolactin rise) ^[1]. Because their receptors differ, they are mechanistically complementary rather than interchangeable — which is also why GHRH analogs and GHRPs are often discussed as stack partners.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is, again, GHRP versus GHRH analog. Tesamorelin is a stabilized GHRH analog acting on the GHRH receptor; ipamorelin is a ghrelin-receptor (GHS-R1a) agonist ^[1]. The cleanest distinction is regulatory and evidentiary: tesamorelin carries a specific approved human indication in its labeled population, whereas ipamorelin has never been approved for any indication and its only Phase 2 trial — for postoperative ileus — missed its primary endpoint ^[7]. Mechanistically the two sit on opposite sides of the growth-hormone-release pathway and, like other GHRH-analog/GHRP pairs, are complementary rather than substitutes.

The human evidence: pharmacology in, efficacy out

Human ipamorelin data is small and, on efficacy, negative. Population PK/PD modeling in healthy male volunteers (n=8 per dose; five 15-minute IV infusions of 4.21-140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life near 2 hours, clearance 0.078 L/h/kg, and steady-state volume of distribution 0.22 L/kg, with the growth-hormone response peaking as a single pulse about 40 minutes post-dose ^[6].

The only published Phase 2 RCT (NCT00672074; 114 bowel-resection patients, 0.03 mg/kg IV twice daily up to 7 days) missed its primary endpoint: median time to first tolerated meal was 25.3 h on ipamorelin versus 32.6 h on placebo, p=0.15 ^[7]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short perioperative window, but no demonstrated efficacy either. Observational reports of growth-hormone-secretagogue combinations raising IGF-1 in hypogonadal men exist ^[13], and andrology reviews discuss the gap between marketed use and approved indications for the class ^[14], but these are not controlled efficacy trials.

The most recent data, and a class-level safety anchor

The freshest in-vivo ipamorelin study is a 2024 ferret experiment: intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48-72 h), with no anti-emetic effect on either acute or delayed emesis — a peripheral anti-cachexia signal without the central anti-nausea action that intracerebroventricular anamorelin showed ^[8]. Recent 2026 reviews place ipamorelin as an investigational growth-hormone-axis secretagogue with preclinical musculoskeletal and metabolic signals, while emphasizing the absence of rigorous human trials and the potential for serious harm ^{[17] [18]}.

The safety anchor that keeps any honest ipamorelin digest grounded is a 28-day integrated study of GSK894281, a different GHS-R1a agonist: it caused dose-dependent myocardial degeneration and necrosis in rats, detectable by histopathology and electron microscopy, with elevated heart-type fatty-acid-binding protein at the top doses ^[9]. Ipamorelin was not the tested compound — but no equivalent long-duration cardiovascular study of ipamorelin exists, which is exactly why chronic systemic dosing warrants scrutiny.